How Entyvio Works

Entyvio (vedolizumab) is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. It is a humanised monoclonal antibody (MAb) that binds specifically to a protein known as α4β7 integrin, which is preferentially expressed on a subset of lymphocytes.

These lymphocytes target the gastrointestinal tract and contribute to the inflammation that is characteristic of ulcerative colitis and Crohn’s disease. When Entyvio binds to α4β7 integrin it inhibits the ability of the lymphocytes to interact with gut endothelial cells and by extension inhibits their ability to cross the endothelium and contribute to disease exacerbation.1

MOA video